Shanghai, China

Xintai Zhao

This inventor holds 1 USPTO granted patent. Top assignee: Shanghai Cancer Institute. Active years: 2006.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xintai Zhao: Innovator in Cancer Research

Introduction

Xintai Zhao is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of cancer research, particularly through his innovative work on human proteins associated with hepatoma.

Latest Patents

Xintai Zhao holds a patent for a human hepatoma associated protein and the polynucleotide encoding said polypeptide. This invention relates to a new kind of human protein associated with hepatoma and the polynucleotide encoding the polypeptide. It also includes a process for producing the polypeptide by recombinant methods. The present invention further relates to methods of applying the polypeptide for the diagnosis and treatment of various diseases, including cancer. Additionally, it encompasses the antagonist of the polypeptide and its therapeutic uses, as well as the use of the polynucleotide encoding the hepatoma associated human protein. He has 1 patent to his name.

Career Highlights

Xintai Zhao is affiliated with the Shanghai Cancer Institute, where he conducts his research and development activities. His work has been instrumental in advancing the understanding of cancer-related proteins and their potential applications in medical diagnostics and therapeutics.

Collaborations

Some of his notable coworkers include Dafang Wan and Jianren Gu, who have collaborated with him on various research projects.

Conclusion

Xintai Zhao's innovative contributions to cancer research highlight the importance of scientific advancements in the fight against diseases. His work continues to pave the way for new diagnostic and therapeutic methods in the medical field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…